ALL NEWS

US experts convene to decide whether to OK Pfizer vaccine

Dec 10, 2020, 2:26 PM
A pharmacist labels syringes in a clean room where doses of COVID-19 vaccines will be handled, Wedn...
A pharmacist labels syringes in a clean room where doses of COVID-19 vaccines will be handled, Wednesday, Dec. 9, 2020, at Mount Sinai Queens hospital in New York. The hospital expects to receive doses once a vaccine gets the emergency green light by U.S. regulators. (AP Photo/Mark Lennihan)
(AP Photo/Mark Lennihan)

WASHINGTON (AP) — A U.S. government advisory panel convened on Thursday to decide whether to endorse large-scale use of Pfizer’s COVID-19 vaccine to help conquer the outbreak that has killed close to 300,000 Americans.

The meeting of outside advisers to the Food and Drug Administration represented the next-to-last hurdle before the expected start of the biggest vaccination campaign in U.S. history. Depending on how fast the FDA signs off on the panel’s recommendation, shots could begin within days.

The FDA panel functions like a science court. During the scheduled daylong session, it was expected to debate and pick apart the data — in public — on whether the vaccine is safe and effective enough to be cleared for emergency use. With unprecedented interest in the normally obscure panel, the FDA broadcast the meeting via Youtube, and thousands logged on.

“The American public demands and deserves a rigorous, comprehensive and independent review of the data,” said FDA’s Dr. Doran Fink, who described agency scientists working nights, weekends and over Thanksgiving to get that done.

The FDA is not required to follow the committee’s advice but is widely expected to do so. Once that happens, the U.S. will begin shipping millions of doses of the shot.

Later this month, the FDA is expected to pass judgment on another vaccine, developed by Moderna and the National Institutes of Health, that has proved about as protective as Pfizer’s. Vaccine candidates by Johnson & Johnson and AstraZeneca are also in the pipeline.

The initial supplies from Pfizer and Moderna will be limited and reserved primarily for health care workers and nursing home patients, with other vulnerable groups next in line until the shots become widely available on demand, something that will probably not happen until the spring.

The meeting of experts on vaccine development, infectious diseases and medical statistics came as the coronavirus continues surging across much of the world, claiming more than 1.5 million lives, including about 290,000 in the U.S.

Hanging over the meeting was a warning from British officials that people with a history of serious allergic reactions shouldn’t get the vaccine. Government authorities there are investigating two reports of reactions that occurred on Tuesday when Britain became the first country in the West to begin mass vaccinations against the scourge.

Pfizer representatives told the panel they are aware of the British reports but have seen no signs of allergic reactions in their trial of the vaccine.

A positive recommendation and speedy U.S. approval appear nearly certain after FDA scientists issued an overwhelmingly positive initial review of the vaccine earlier this week.

FDA said results from Pfizer’s large, ongoing study showed that the shot, which was developed with Germany’s BioNTech, was more than 90% effective across people of different ages, races and underlying health conditions, including diabetes and obesity. No major safety problems were uncovered. Common side effects included fever, fatigue and pain at the injection site.

“The data presented in the briefing report were consistent with what we heard before and are really exciting,” said Dr. William Moss, head of Johns Hopkins University’s International Vaccine Access Center. “Nothing that I see would delay an emergency use authorization.”

The meeting also represented an opportunity for regulators to try to boost public confidence in the breakneck development process that has produced the Pfizer vaccine and a string of other upcoming shots with remarkable speed — less than a year after the virus was identified.

The FDA has also faced weeks of criticism from President Donald Trump for not rushing out a vaccine before Election Day.

“There have been a lot of questions about why it takes us so long or are we being rigorous enough?” FDA Commissioner Stephen Hahn said in an interview. “I’m hoping that people will see with our transparency that we have taken a very rigorous stance on this.”

Hahn said the agency had already teed up the process to authorize the vaccine by filling out all the legal paperwork in advance, regardless of the ultimate decision.

On Thursday’s agenda:

RARE ADVERSE REACTIONS

The FDA uncovered no major safety problems in its review of Pfizer’s 44,000-person study, including no allergic reactions of the type reported in Britain. But such studies can’t detect rare problems that might only affect a tiny slice of the general population.

FDA reviewers noted four cases of Bell’s palsy that occurred among people getting the vaccine. They concluded the cases were probably unrelated to the vaccine because they occurred at rates that would be expected without any medical intervention. But the agency did say cases of the nerve disorder should be tracked, given that other vaccines can cause the problem.

EFFICACY QUESTIONS

The FDA found the vaccine highly effective across various demographic groups. But it is unclear how well the vaccine works in people with HIV and other immune-system disorders.

The study excluded pregnant women, but experts were expected to tease apart the data for any hints in case women get vaccinated before realizing they’re pregnant.

A study of children as young as 12 is underway.

IMPACT OF EMERGENCY AUTHORIZATION

Answering some of these questions will require keeping Pfizer’s study going for many more months. And the FDA has made clear it wants vaccine developers to continue tracking people who got their shot and those who received a placebo for as long as possible, to compare their outcomes.

But Pfizer and BioNTech said Thursday they have an “ethical responsibility” to switch the 22,000 placebo recipients to real shots after FDA gives the vaccine its OK.

In a compromise, the companies proposed moving those patients to the vaccine group gradually, giving participants priority according to age, health conditions and other factors. Under that plan, 70-year-old participants would cross over before healthy 30-year-olds.
___
AP writer David Koenig contributed to this story from Dallas.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.

Today’s Top Stories

All News

Nichole Thomas, Pioneer Park Coalition member and Latter-day Brides owner, speaks during a Pioneer ...
Mark Jones

Pioneer Park Coalition announces plan to combat crime, homelessness

On Thursday, the Pioneer Park Coalition announced a three-pronged plan to combat homelessness and crime in Salt Lake City.
1 day ago
Salt Lake City police are investigating a shooting Thursday evening, Oct. 6, 2022, at Meadows Park....
Mark Jones

Salt Lake City Police investigating shooting at Meadows Park

One teenager suffered non-life-threatening injuries following a shooting Thursday evening at Meadows Park.
1 day ago
Salt Lake County DA Sim Gill speaking behind a podium...
Devin Oldroyd

Salt Lake County DA discusses Biden’s pardon of marijuana possession

Following President Biden announced pardons for thousands of people convicted of marijuana possession federally, Salt Lake County District Attorney Sim Gill discusses what this means for the Beehive State.
1 day ago
Police in Tooele are looking for an armed robbery suspect that forced three schools into lockdown o...
Mark Jones

Search for wanted fugitive in Tooele is unsuccessful

Law enforcement personnel in Tooele conducted a search for a fugitive on Thursday afternoon. The search was unsuccessful.
1 day ago
Serial Bank Robber...
Mark Jones

FBI seeking information on whereabouts of serial bank robber

The FBI says a serial bank robber has recently robbed a pair of banks in Salt Lake City. Authorities are seeking the public's assistance in locating the individual responsible.
1 day ago
DACA march...
Alejandro Lucero

DACA ruled illegal by court, but current “Dreamers” still protected

Current Dreamers are still protected by the law and can continue to renew their applications, but new applicants are barred.
1 day ago

Sponsored Articles

Young woman receiving laser treatment...
Form Derm Spa

How facial plastic surgery and skincare are joining forces

Facial plastic surgery is not only about looking good but about feeling good too. The medical team at Form Spa are trained to help you reach your aesthetic outcomes through surgery and through skincare and dermatology, too.
large group of friends tohether in a park having fun...
BYU MBA at the Marriott School of Business

What differentiates BYU’s MBA program from other MBA programs

Commitment to service is at the heart of BYU’s MBA program, which makes it stand out among other MBA programs across the country.
a worker with a drill in an orange helmet installs a door in the house...
Price's Guaranteed Doors

Home improvement tip: Increase the value of your home by weatherproofing doors

Make sure your home is comfortable before the winter! Seasonal maintenance keeps your home up to date. Read our tips on weatherproofing doors.
Curb Appeal...
Price's Guaranteed Doors

How to have the best of both worlds for your house | Home security and curb appeal

Protect your home and improve its curb appeal with the latest security solutions like beautiful garage doors and increased security systems.
A paper reading IRS, internal revenue service is pictured...
Jordan Wilcox

The best strategies for dealing with IRS tax harassment | You have options!

Learn how to deal with IRS tax harassment. This guide will teach you how to stop IRS phone calls and letters, and how to handle an IRS audit.
spend a day at Bear Lake...
Bear Lake Convention and Visitors Bureau

You’ll love spending the day at Bear Lake | How to spend a day at Bear Lake

Bear Lake is a place that needs to be experienced. Spend a day at Bear Lake.
US experts convene to decide whether to OK Pfizer vaccine